Xolair (Omalizumab) for Food Allergies

Overview
Xolair is approved by the U.S. Food and Drug Administration (FDA) to treat immunoglobulin E (IgE)-mediated food allergy in adults and children aged 1 year and older. It can help reduce allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods. It is still important to avoid all known food allergens while taking Xolair. Xolair is also known by its drug name, omalizumab.

Xolair is an anti-IgE antibody that targets IgE, a key player in the allergic response. By reducing the amount of IgE available to trigger allergic reactions, Xolair helps to manage the symptoms associated with IgE-mediated food allergies.

How do I take it?
Xolair is administered as a subcutaneous (under the skin) injection every two or four weeks. The specific dose and frequency will depend on your body weight and the results of IgE level tests taken before you start the medication.

Always take the medication exactly as prescribed by a health care provider.

Side effects
Common side effects of Xolair include injection site reactions and fever. 

Rare but serious side effects may include anaphylaxis, a severe allergic reaction that can be life-threatening. It is crucial to begin taking Xolair therapy in a health care setting where health care professionals can respond to any signs of anaphylaxis. If you experience trouble breathing, low blood pressure, a rash or hives, fainting, or swelling of the throat or tongue, seek immediate medical care.

For more information about this treatment, visit:

Xolair (Omalizumab) — Genentech 

Omalizumab (Subcutaneous Route) — Mayo Clinic